Gilead Sciences, Inc. (BCBA:GILD)

Market Cap	268.11T +120.7%
Revenue (ttm)	39.86T +2.8%
Net Income	11.11T +6,336.5%
EPS	8,802.50 +6,514.1%
Shares Out	n/a
PE Ratio	24.12
Forward PE	18.89
Dividend	641.73 (1.15%)
Ex-Dividend Date	Dec 15, 2025

Volume	151
Average Volume	445
Open	55,550
Previous Close	56,050
Day's Range	54,900 - 55,550
52-Week Range	27,675 - 57,775
Beta	n/a
RSI	65.51
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD